Drug Development / Yuhan Corporation
Pharma Firms Target FGF21 for Liver, Metabolic Diseases
With the emergence of 'Resdipra' in 2024, the era of treatments for Metabolic Associated Steatohepatitis (MASH) has begun, elevating the liver and metabolic disease sector to a key battleground in the pharmaceutical industry. Major pharmaceutical companies are aggressively pursuing acquisition and l
2025.12.10